With the emergence of immunotherapy and the encouraging results from the CASPIAN and IMpower133 trials, regimens combining chemotherapy with anti-programmed death ligand 1 (PD-L1) antibodies might also be effective in primary extrapulmonary small cell carcinoma (ESCC) treatment [20, 21]. Here, CD274 is linked to small cell carcinoma.